The Outlook for Immune Checkpoint Targeting Strategies in Colorectal Cancer

Published

Journal Article (Review)

© 2016, Springer Science+Business Media New York. Encouraging clinical activity for checkpoint blockade in melanoma, lung cancer, and a growing list of other malignancies has supported enthusiasm for testing this strategy in colorectal cancer. Although frequent observations of T cell infiltration into colorectal cancer and a well-established list of target antigens suggest colorectal cancer should be amenable to this approach, there was limited clinical evidence until recent demonstration of substantial activity for anti-PD-1 antibody therapy in microsatellite instability high colorectal cancers. Addition of other therapeutic modalities such as targeted therapy, other checkpoint molecules, or other immunotherapies to anti-PD-1 antibodies is currently under evaluation with the hope that it will expand the possible spectrum of colorectal cancers treatable with checkpoint blockade.

Full Text

Duke Authors

Cited Authors

  • Morse, MA

Published Date

  • February 1, 2016

Published In

Volume / Issue

  • 12 / 1

Start / End Page

  • 51 - 56

Electronic International Standard Serial Number (EISSN)

  • 1556-3804

International Standard Serial Number (ISSN)

  • 1556-3790

Digital Object Identifier (DOI)

  • 10.1007/s11888-016-0309-6

Citation Source

  • Scopus